Article
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2015
Tanaka Kosuke, Hida Toyoaki, Oya Yuko, Oguri Tomoyo, Yoshida Tatsuya, Shimizu Junichi, Horio Yoshitsugu, Hata Akito, Kaji Reiko, Fujita Shiro, Sekido Yoshitaka, Kodaira Takeshi, Kokubo Masaki, Katakami Nobuyuki, Yatabe Yasushi
Abstract excerpt
BACKGROUND: Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung adenocarcinoma; however, little has been reported about the impact of epidermal growth factor receptor (EGFR) mutation on CRT efficacy. METHODS: From 2006 to 2013, we retrospectively screened 104 unresectable stage III adenocarcinoma patients who were examined for EGFR mutation status and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.